Department of Radiology, Michigan Medicine, Ann Arbor, Michigan.
Department of Cardiac Surgery, Michigan Medicine, Ann Arbor, Michigan.
Ann Thorac Surg. 2021 Jan;111(1):237-245. doi: 10.1016/j.athoracsur.2020.05.074. Epub 2020 Jul 6.
The short-term and intermediate-term outcomes of two distinct approaches to thoracic endovascular aortic repair (TEVAR) for descending aortic aneurysms in patients with compromised distal landing zones are reported.
Fifty-one patients (38 female, average age 72 ± 9 years) underwent 55 TEVARs (2008 to 2018) for aneurysmal disease. Inclusion criteria consisted of TEVAR in a compromised distal landing zone, defined as follows: diameter 3.5 cm or greater; cross-sectional thrombus 50% or greater; or 25% or greater circumferential mural calcification in the 2 cm supraceliac aorta; or tortuosity index of 1.1 or more over the 10 cm supraceliac aorta. Treatment cohorts were (1) TEVAR alone (n = 29), and (2) TEVAR with adjunct consisting of visceral snorkel graft with distal stent extension (n = 20) or EndoAnchors (Medtronic, Minneapolis, MN [n = 6]).
Perioperative complication rate was 20%. Thirty-day mortality was 5% including one access-site related intraoperative death and one postoperative death from embolic mesenteric ischemia. Median clinical follow-up was 2.2 years. Intermediate-term outcomes include type 1B endoleaks, 35%; 0.5 cm or more per year maximal aortic diameter growth, 9%; reintervention, 15%; and all-cause mortality, 25%. The distal landing zone diameter increased by 0.3 cm per year in the TEVAR alone cohort; however, it decreased by 0.1 cm per year in the adjunct cohort ( P = .04).
Thoracic endovascular aortic repair is a viable alternative for the treatment of thoracoabdominal aortic aneurysms in patients with compromised distal landing zones, although these patients may benefit significantly from the development of branched thoracoabdominal devices. In the interim, the use of TEVAR adjuncts may limit progressive degeneration of the distal landing zone in this patient population.
本研究报告了两种不同方法治疗累及远端锚定区的降主动脉夹层动脉瘤的短期和中期结果。
51 例患者(38 例女性,平均年龄 72±9 岁)接受了 55 例胸主动脉腔内修复术(TEVAR)(2008 年至 2018 年)治疗夹层动脉瘤。纳入标准为累及远端锚定区的 TEVAR,定义如下:直径≥3.5cm;横截面血栓形成≥50%;或在 2cm 以上的主动脉腔内有≥25%的环形壁钙化;或在 10cm 以上的主动脉腔内有≥1.1 的扭曲指数。治疗队列为(1)单纯 TEVAR 组(n=29)和(2)TEVAR 加用内脏支架延伸的血管吊带(n=20)或 EndoAnchors(Medtronic,明尼苏达州明尼阿波利斯市)组(n=6)。
围手术期并发症发生率为 20%。30 天死亡率为 5%,包括 1 例术中与入路相关的死亡和 1 例术后肠系膜缺血性栓塞死亡。中位临床随访时间为 2.2 年。中期结果包括 1 型 B 型内漏 35%;每年主动脉最大直径增长≥0.5cm 9%;再干预 15%;全因死亡率 25%。单纯 TEVAR 组的远端锚定区直径每年增加 0.3cm;而在加用组,远端锚定区直径每年减少 0.1cm(P=0.04)。
胸主动脉腔内修复术是治疗累及远端锚定区的胸腹主动脉瘤的一种可行方法,尽管这些患者可能从分支胸腹主动脉器械的发展中显著获益。在这期间,TEVAR 加用器械可能会限制该患者人群中远端锚定区的进行性恶化。